CDEK
← All drugs Report issue

tamsulosin

Trade name: flomax

Small moleculeapproved

Approved

Apr 15, 1997

Tamsulosin, a sulfamoylphenethylamine-derivative alpha-adrenoceptor blocker with enhanced specificity for the alpha-adrenoceptors of the prostate, is commonly used to treat benign prostatic hyperplasia (BPH). The drug is commercially available in a racemic mixture of 2 isomers, and is pharmacologically related to doxazocin, prazosin, and terazosin. However, unlike these drugs, tamsulosin has a higher affinity for the alpha-1A- adrenergic receptors, which are located in vascular smooth muscle. Studies show that tamsulosin has about 12 times greater affinity for alpha-1 adrenergic receptors in the prostate than those in the aorta, which may result in a reduced incidence of adverse cardiovascular effects. Tamsulosin is sold under the trade name Flomax. — NCATS

Clinical trial activity

232 trials · 158 clinical orgs · 30 marketing orgs

Phase 1
64
Phase 2
71
Phase 3
53
Phase 4
67

Earliest trial started Sep 30, 1997 (NCT04552431)

Timeline

1990s

  1. Jan 1, 1997

    Earliest Phase 2 Sponsor(trial)

  2. Apr 15, 1997

    Sanofi-Aventis — Earliest FDA Approval

  3. Apr 15, 1997

    Sanofi-Aventis — NDA Secondary Org

  4. Apr 15, 1997

    Sanofi-Aventis — NDA Organization

  5. Apr 15, 1997

    Sanofi — Marketing Organization

  6. Apr 15, 1997

    Sanofi — NDA Secondary Org

  7. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Mar 2, 2010

    Impax Laboratories — Marketing Organization

  2. Apr 27, 2010

    Mylan — Marketing Organization

  3. Apr 27, 2010

    Sandoz — Marketing Organization

  4. Apr 27, 2010

    Byondis — Marketing Organization

  5. Apr 27, 2010

    Teva — Marketing Organization

  6. Apr 27, 2010

    Wockhardt — Marketing Organization

  7. Apr 27, 2010

    Novartis — Marketing Organization

  8. Apr 27, 2010

    PHARMOBEDIENT — Marketing Organization

  9. Apr 27, 2010

    Sciegen Pharmaceticals — Marketing Organization

  10. Jun 14, 2010

    GlaxoSmithKline — Marketing Organization

  11. Jun 14, 2010

    Woodward — NDA Secondary Org

  12. Jun 14, 2010

    Waylis Therap — NDA Secondary Org

  13. Jul 15, 2010

    Sun Pharmaceuticals — Marketing Organization

  14. Jan 4, 2013

    Anchen Pharmaceuticals, Inc — Marketing Organization

  15. Jan 4, 2013

    Par Pharmaceuticals — Marketing Organization

  16. Jan 4, 2013

    PH HEALTH — Marketing Organization

  17. Apr 30, 2013

    Aurobindo Pharma — Marketing Organization

  18. Nov 20, 2015

    Actavis — Marketing Organization

  19. Nov 20, 2015

    Allergan PLC (2015) — Marketing Organization

  20. Jan 20, 2017

    Macleods Pharmaceuticals, Ltd — Marketing Organization

  21. Jan 20, 2017

    Neogen — Marketing Organization

  22. Aug 11, 2017

    Alkem Labs Ltd — Marketing Organization

  23. May 24, 2018

    Zydus Discovery DMCC — Marketing Organization

  24. Oct 17, 2019

    Anbison Lab — Marketing Organization

  25. Oct 17, 2019

    Chartwell Pharmaceuticals — Marketing Organization

2020s

  1. May 4, 2022

    ACME Laboratories — Marketing Organization

  2. May 4, 2022

    Ascent Pharmahealth — Marketing Organization

  3. May 1, 2025

    Rising Pharmaceuticals — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Combination products

Approval history

  • approvedApr 15, 1997

Chemistry & pharmacology

Loading structure…

SMILES

CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1
Mol. weight
408.52 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
  • 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
  • 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
  • 5-((2r)-2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxy-benzenesulfonamide
  • alphacard mr
  • asp4901
  • bazetham mr
  • contiflo xl
  • cositam xl
  • diffundox
  • faramsil
  • flectone xl
  • flomax
  • flomax
  • flomax
  • flomax
  • flomax
  • flomax mr
  • flomax mr
  • flomax relief mr
  • flomaxtra xl
  • flowmax
  • flowmax
  • galebon
  • losinate mr
  • ly-253351
  • ly-253351
  • ly 253352
  • ly-253352
  • ly-253352
  • maxtron
  • morvesin xl
  • omnic mr
  • pamsvax xl
  • petyme
  • pinexel pr
  • prosurin xl
  • (r)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
  • (r)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
  • r-(-)-ym-12617
  • r-(-)-ym-12617
  • stronazon
  • tabphyn mr
  • tamfrex xl
  • tamsulosin
  • tamsulosin
  • tamsulosin
  • tamsulosin
  • tamsulosin
  • tamsulosin
  • tamsulosin
  • tamsulosin
  • tamsulosin
  • tamsulosin
  • tamsulosina
  • tamsulosina
  • tamsulosine
  • tamsulosine
  • tamsulosin hcl
  • tamsulosin hcl
  • tamsulosin hcl
  • tamsulosin hydrochloride
  • tamsulosin hydrochloride
  • tamsulosin hydrochloride
  • tamsulosin hydrochloride
  • tamsulosin hydrochloride
  • tamsulosin hydrochloride
  • tamsulosinum
  • tamsulosinum
  • tamurex
  • tansulosine
  • ym-12617-1
  • ym-12617-1
  • ym 617
  • ym-617
  • ym-617
  • ym-617

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06546735Phase 3Nov 30, 2026Eurofarma Laboratorios S.A.
NCT07276919Phase 4Feb 1, 2026Peking University, Shanxi Medical University
NCT07310797Phase 4Jan 1, 2026Tzu Chi University
NCT07308002Phase 4Jan 1, 2026Mansoura University
NCT07174349Phase 4Dec 1, 2025Mayo Clinic
NCT07156916Phase 1Sep 8, 2025Menarini Group, Yerevan State Medical University, Armenia
NCT07091669Phase 1Jun 16, 2025Menarini Group, Yerevan State Medical University, Armenia
NCT06966804Phase 3Jun 1, 2025Penang Medical College
NCT06865430N/AMar 4, 2025University of Ankara
NCT07146711Phase 1Mar 3, 2025Menarini Group
NCT06264414Phase 3Feb 28, 2025EMS S/A
NCT06843538Phase 3Feb 3, 2025TriHealth
NCT06803030Phase 3Feb 1, 2025Government of Nepal, NAMS Bir Hospital
NCT07307261N/AOct 10, 2024South Valley University
NCT06262048Phase 2Oct 1, 2024University of Western Ontario
NCT07114848Phase 4Jun 13, 2024Liaquat University of Medical & Health Sciences
NCT06867315N/AMay 29, 2024First People's Hospital of Hangzhou, Fujian Provincial Hospital, Jiao Tong University, University of Science and Technology of China, Zhejiang University
NCT06955533N/AApr 1, 2024Ain Shams University
NCT06257576Phase 3Feb 26, 2024Emory University
NCT05657990Early Phase 1 (Phase 1)Dec 20, 2023Hackensack University Medical Center
Showing 20 of 232 trials
Page 1 / 12

Organizations

Research & Development (158)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstellasFor profit242152005
GlaxoSmithKlineFor profit201832003
Boehringer IngelheimFor profit181741998
Mansoura UniversityAcademic/Hospital8832013
Chong Kun Dang PharmaceuticalFor profit7722014
Hanmi PharmaceuticalFor profit7722014
Seoul National UniversityAcademic/Hospital6232007
Eli LillyFor profit4422007
Jeil Pharmaceutical Co., Ltd.For profit4422014
Sungkyunkwan UniversityAcademic/Hospital4422008
Yonsei UniversityAcademic/Hospital4212012
Case Western Reserve UniversityAcademic/Hospital3222005
Chonbuk National UniversityAcademic/Hospital3012013
Emory UniversityAcademic/Hospital3232005
GL Pharm Tech CorporationFor profit3222012
Menarini GroupFor profit3312025
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government3221997
University of Alabama, BirminghamAcademic/Hospital3232008
University of RochesterAcademic/Hospital3122005
University of UlsanAcademic/Hospital3122010
158 organizations
Page 1 / 8

Marketing (35)

OrganizationOrg typeRelationshipDate
ACME LaboratoriesFor profitMKTGMay 4, 2022
ActavisFor profitMKTGNov 20, 2015
Alkem Labs LtdFor profitMKTGAug 11, 2017
Allergan PLC (2015)For profitMKTGNov 20, 2015
Anbison LabFor profitMKTGOct 17, 2019
Anchen Pharmaceuticals, IncFor profitMKTGJan 4, 2013
Ascent PharmahealthFor profitMKTGMay 4, 2022
Aurobindo PharmaFor profitMKTGApr 30, 2013
Aurobindo PharmaFor profitSYNJul 18, 2024
ByondisFor profitMKTGApr 27, 2010
ByondisFor profitSYNApr 27, 2010
Chartwell PharmaceuticalsFor profitMKTGOct 17, 2019
GlaxoSmithKlineFor profitMKTGJun 14, 2010
Impax LaboratoriesFor profitMKTGMar 2, 2010
Macleods Pharmaceuticals, LtdFor profitMKTGJan 20, 2017
MylanFor profitMKTGApr 27, 2010
NeogenFor profitMKTGJan 20, 2017
NovartisFor profitMKTGApr 27, 2010
PH HEALTHFor profitMKTGJan 4, 2013
PHARMOBEDIENTFor profitMKTGApr 27, 2010
Par PharmaceuticalsFor profitMKTGJan 4, 2013
Rising PharmaceuticalsFor profitMKTGMay 1, 2025
SandozFor profitMKTGApr 27, 2010
SanofiFor profitMKTGApr 15, 1997
SanofiFor profitNDA2Apr 15, 1997
Sanofi-AventisFor profitNDA2Apr 15, 1997
Sanofi-AventisFor profitNDAApr 15, 1997
Sciegen PharmaceticalsFor profitMKTGApr 27, 2010
Sun PharmaceuticalsFor profitMKTGJul 15, 2010
TevaFor profitMKTGApr 27, 2010
Waylis TherapFor profitNDA2Jun 14, 2010
WockhardtFor profitMKTGApr 27, 2010
WoodwardFor profitNDA2Jun 14, 2010
Zydus Discovery DMCCFor profitMKTGMay 24, 2018
Zydus Discovery DMCCFor profitSYNApr 27, 2010